In 2005, two separate groups of researchers demonstrated the potential of PARP1 inhibition as a targeted, synthetic lethal approach to treating BRCA-mutant tumours: the mouse models of Bryant et al. and Farmer et al. [16]. This evidence concerns the gene PARP1 and neoplasm.